Sign in

NCT06881966Not yet recruiting

The Effect of Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis

The Effect of Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis: A Study Protocol of a Double-blinded Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 10 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The aim of this double-blinded randomized controlled trial (RCT) was to assess the effect of omega-3 intake versus placebo among patients with RA on the primary outcome of disease activity, and the secondary outcomes of function, fatigue and sleep. This is a prospective, comparative, randomized study, that will be conducted in a single centre (the Rheumatology Department of Charles Nicolle Hospital) during a period of 10 months. This double-blinded RCT will include adult patients diagnosed with RA according to the Association of Rheumatology America (ACR) criteria, attending the Rheumatology Department of Charles Nicolle Hospital. All included patients will be randomized into two groups: an intervention group who will receive omega-3 supplementation and a control group who will receive placebo supplementation, over a period of 3 months. The placebo capsules will be olive oil-based and will have the same visual as the omega-3 capsules. They will be developed by Vital Company. Patients in the intervention group will consume 2 omega-3 capsules daily, which contain 36% and 24% of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively. The dose of omega-3 and placebo will be constant throughout the study period. Patients will be evaluated at baseline and after 3 months of omega-3 or placebo intake, by a questionnaire performed by a research assistant, which contains the following evaluation parameters: * Assessment of dietary and non-study supplemental intakes of marine omega-3 fatty acids * Assessment of disease activity * Assessment of function * Assessment of sleep quality * Assessment of fatigue

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
180 (estimated)
First submitted
7 Mar 2025
Start date
1 Sept 2025
Primary completion date
1 Dec 2025
Lead sponsor
Hopital Charles Nicolle
NCT number
NCT06881966

What you commit to

  • Study type: Interventional
  • Planned participants: 180
  • From 1 Sept 2025 to the primary completion date, 1 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients treated with anticoagulants and coagulation disorders

Other illness

  • Patients with allergy to fish and seafood
  • Patients with severe hepatic impairment
  • Patients with severe renal impairment

Other

  • Patients with severe hypertriglyceridemia associated with pancreatitis
  • Current pregnancy or breastfeeding.

Who the study is looking for

  • Adult patients ≥ 18 years
  • Patients diagnosed with RA according to the Association of Rheumatology America (ACR) criteria, attending the Rheumatology Department of Charles Nicolle Hospital.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Charles Nicolle hospital
Coordinator of this site? Confirm its status
TunisTunisiaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.